Foghorn Therapeutics announced that the first patient has been dosed with FHD-909 in the Phase 1 trial for SMARCA4 mutated cancers, with non-small cell lung cancer, NSCLC, as the primary target patient population. FHD-909 is a first-in-class oral, highly potent compound that demonstrates high selectivity for SMARCA2 over SMARCA4, a closely related protein.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX: